首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >97%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL36B |
| Uniprot No | Q9NZH7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-157aa |
| 氨基酸序列 | MNPQREAAPK SYAIRDSRQM VWVLSGNSLI AAPLSRSIKP VTLHLIACRD TEFSDKEKGN MVYLGIKGKD LCLFCAEIQG KPTLQLKEKN IMDLYVEKKA QKPFLFFHNK EGSTSVFQSV SYPGWFIATS TTSGQPIFLT KERGITNNTN FYLDSVE |
| 预测分子量 | 17.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"IL-36β amplifies the pro-inflammatory response in human rheumatoid arthritis synovial fibroblasts by activating the MAPK and NF-κB pathways"**
*Authors: Li X, et al.*
摘要：研究探讨了重组IL-36β蛋白对类风湿关节炎滑膜成纤维细胞的作用，发现其通过激活MAPK和NF-κB信号通路促进炎症因子(如IL-6、IL-8)的释放，提示IL-36β在关节炎病理中的关键角色。
2. **"Recombinant IL-36β induces chemokine production and neutrophil recruitment in murine psoriasis-like skin inflammation"**
*Authors: Bridgewood C, et al.*
摘要：通过小鼠银屑病模型，发现局部注射重组IL-36β可诱导皮肤中CXCL1、CXCL2等趋化因子表达，并招募中性粒细胞，证实IL-36β驱动银屑病相关炎症反应的机制。
3. **"Structural characterization and functional analysis of recombinant human IL-36β cytokine"**
*Authors: Günther S, et al.*
摘要：报道了人源重组IL-36β蛋白的晶体结构解析，揭示其与IL-36R受体结合的关键区域，并通过体外实验证明其促炎活性依赖于受体复合物的形成。
4. **"IL-36β promotes fibroblast senescence and exacerbates pulmonary fibrosis in a senescence-associated secretory phenotype (SASP)-dependent manner"**
*Authors: Yamamoto Y, et al.*
摘要：发现重组IL-36β通过诱导肺成纤维细胞衰老及SASP表型释放促纤维化因子(如TGF-β)，加重肺纤维化进程，为靶向IL-36β治疗纤维化疾病提供依据。
IL-36β (Interleukin-36 beta), a member of the IL-1 cytokine family, plays a critical role in regulating inflammatory and immune responses. It is primarily expressed in epithelial tissues, such as skin, lung, and gut, and is involved in host defense against pathogens. IL-36β is synthesized as an inactive precursor protein (pro-IL-36β) that requires proteolytic cleavage (e.g., by neutrophil elastase or cathepsin S) to become biologically active. The mature cytokine binds to the IL-36 receptor (IL-36R), initiating signaling cascades (e.g., NF-κB, MAPK) that drive the production of pro-inflammatory mediators, chemokines, and antimicrobial peptides.
Research highlights its significance in inflammatory skin disorders, particularly psoriasis, where IL-36β overexpression correlates with disease severity. It also contributes to pathologies in chronic lung diseases, rheumatoid arthritis, and inflammatory bowel disease. Recombinant IL-36β protein, produced via expression systems like *E. coli* or mammalian cells, enables mechanistic studies *in vitro* and *in vivo*. Its applications include investigating signaling pathways, screening therapeutic inhibitors, and modeling disease mechanisms. However, excessive IL-36β activity may exacerbate inflammation, making it a potential therapeutic target. Neutralizing antibodies or receptor antagonists targeting IL-36β/IL-36R are under exploration for treating IL-36-driven disorders. As a research tool, recombinant IL-36β facilitates the development of precision therapies aimed at modulating dysregulated immune responses in chronic inflammatory diseases.
×
